Radiological Case: Multiple Myeloma Radiological Case: Multiple Myeloma
This 93-year-old male initially presented with clinical findings and history most suggestive of genitourinary pathology. How was the eventual diagnosis of multiple myeloma made?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2018 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Vaccine Strategy Effective in Smoldering Myeloma
The PVX-410 vaccine shows immune responses in a patient population with smoldering myeloma. (Source: CancerNetwork)
Source: CancerNetwork - September 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Prescription Drug Coverage Key in Multiple Myeloma Therapy
A study shows prescription drug coverage leads to better survival among Medicare beneficiaries with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - September 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Quiz: Understanding Epigenetics and Genomics of Multiple Myeloma
How much do you know about the genomics of multiple myeloma? Take our latest quiz to sharpen your knowledge. (Source: CancerNetwork)
Source: CancerNetwork - September 7, 2018 Category: Cancer & Oncology Source Type: news

Leukogene Therapeutics receives funding to develop compound for resistant multiple myeloma
(Medical University of South Carolina) Leukogene Therapeutics, Inc., a start-up company founded by a Medical University of South Carolina researcher, will optimize a promising compound for combating resistance in the treatment of multiple myeloma and other cancers with funding from an STTR grant. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2018 Category: International Medicine & Public Health Source Type: news

An Integrative Multiomics Approach to Multiple Myeloma
A study shows comprehensive sequencing approach can identify treatment options in patients with relapsed and/or refractory myeloma. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Amgen Submits Supplemental New Drug Application For KYPROLIS ® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Filing Based on Data From Phase 3 Head-to-Head A.R.R.O.W. Study THOUSAND OAKS, Calif., Aug. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the Prescribing Information for KYPROLIS® (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (Kd) for patients with relapsed or refractory multiple myeloma. The sNDA is based on data from the Phase 3 A.R.R.O.W. trial, demonstrating KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-weekly Kd) ...
Source: Amgen News Release - August 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Ask Well: How Do You Die From Leukemia?
Though survival rates have improved markedly, a variety of problems can cause death. (Source: NYT Health)
Source: NYT Health - August 17, 2018 Category: Consumer Health News Authors: MIKKAEL A. SEKERES, M.D. Tags: Leukemia Antibiotics Cancer Multiple Myeloma Bone Marrow Deaths (Fatalities) Longevity Infections Heart Source Type: news

Bortezomib-Based Therapy Effective for Relapsed/Refractory Myeloma
Relapsed or refractory multiple myeloma patients experience high response rates, overall survival with bortezomib-based therapy. (Source: CancerNetwork)
Source: CancerNetwork - August 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Rare cancer could be caught early using simple blood tests
(University of Exeter) A pioneering study into myeloma, a rare cancer, could lead to GPs using simple blood tests to improve early diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 13, 2018 Category: Cancer & Oncology Source Type: news

NUS develop AI platform to identify personalized drug combinations for myeloma patients
(National University of Singapore) A multidisciplinary team of researchers from the National University of Singapore has developed an artificial intelligence technology platform that could potentially change the way drug combinations are being designed, hence enabling doctors to determine the most effective drug combination for a patient quickly. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 12, 2018 Category: International Medicine & Public Health Source Type: news

Resilience Important Aspect of Improved QOL for Myeloma
A high level of resilience was associated with a better mental and physical health-related quality of life among patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Quiz: Managing Previously Treated Multiple Myeloma
Are you up-to-date on treatment regimens for previously treated multiple myeloma? Take our latest quiz to sharpen your knowledge. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2018 Category: Cancer & Oncology Source Type: news

New RNA & DNA-sequencing platform matches thousands of drugs to late-stage cancer patients
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A comprehensive RNA and DNA sequencing platform benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them, according to results from a clinical trial published in JCO Precision Oncology in August. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 8, 2018 Category: Biology Source Type: news

Computational platform optimizes multiple myeloma treatments
(American Association for the Advancement of Science) Masturah Bte Mohd Abdul Rashid and colleagues have developed a new platform that optimizes drug combinations for the treatment of multiple myeloma (MM), an incurable blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 8, 2018 Category: Cancer & Oncology Source Type: news

Radiological Case: Extraosseous Multiple Myeloma Radiological Case: Extraosseous Multiple Myeloma
Review the common imaging findings for extraosseous myeloma in this case of a woman who presented with unexplained weight loss, chills, night sweats, fatigue, and pain at the base of her tongue.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 3, 2018 Category: Radiology Tags: Radiology Journal Article Source Type: news

Acute Kidney Injury in Patients With Cancer
Acute kidney injury (AKI) is a common complication in cancer patients and occurs in up to 30% of patients during their disease course. Multiple myeloma, leukemia/lymphoma, renal cell carcinoma, and hematopoietic stem cell transplantation are commonly associated with the development of AKI.07/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 19, 2018 Category: Urology & Nephrology Source Type: news

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP ™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma
Discussion With Doctor to Create Individualized Treatment Plan Don Baylor Jr., Son of Former MLB Most Valuable Player Don Baylor, Honors Late Father's Legacy by Raising Multiple Myeloma Awareness Through Campaign Amgen to Recognize Local Multiple Myeloma Communities at Select MLB Games in 2018 THOUSAND OAKS, Calif., July 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create their Most Valuable Plan, an individualized approach for managing their disease. Multiple myeloma is an incurable blood ... (Source: Amgen News Release)
Source: Amgen News Release - July 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
NEWTON, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S.... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 18, 2018 Category: Drugs & Pharmacology Source Type: news

A 62-Year-Old Man Who Demands Testing: USMLE Question A 62-Year-Old Man Who Demands Testing: USMLE Question
A 62-year-old man who has no acute complaints demands testing for multiple myeloma, due to his father's death. What do his test results show?Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2018 Category: Consumer Health News Tags: Med Students Interactive Quiz Source Type: news

Looking at the urine and blood may be best in diagnosing myeloma
(Medical College of Georgia at Augusta University) When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, pathologists say. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 13, 2018 Category: Cancer & Oncology Source Type: news

Quiz: Understand the Role of Adipose Tissue in Multiple Myeloma
Our latest quiz highlights the role of bone marrow adiposity in patients with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Ixazomib-Based Regimen Is Promising in Newly Diagnosed Multiple Myeloma
Investigators concluded ixazomib “may offer a more convenient, active, and well-tolerated alternative to a parenterally administered PI in this setting.” (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Multiple Myeloma Incidence Increasing Worldwide, Especially in the US
From 1990 to 2016, incident cases of multiple myeloma increased by 126% globally, while deaths increased 94%. The US had the most incident cases and deaths. (Source: CancerNetwork)
Source: CancerNetwork - July 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Gene Mutations Dictate Treatment in NCI Clinical Trial
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - July 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA-NCI Team Warns Against Single-Arm Pembrolizumab Trials in Multiple Myeloma
An analysis by FDA and NCI investigators recommended further study of the utility of immunotherapy in patients unable to mount adequate immune responses. (Source: CancerNetwork)
Source: CancerNetwork - July 3, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Medical News Today: What types of blood disorders are there?
When the cells in the blood do not function as they should, it is possible a person has a blood disorder. Examples include leukemia, lymphoma, and myeloma. Common blood disorder symptoms include unexplained exhaustion and weight loss. Learn more about the types of blood disorder and the signs to look out for here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 26, 2018 Category: Consumer Health News Tags: Blood / Hematology Source Type: news

Can We Afford the Cost of Myeloma Therapy? Can We Afford the Cost of Myeloma Therapy?
Two experts square off on the issue of drug cost for multiple myeloma -- is care really not affordable, or are most patients able to access treatment?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Quiz: Multiple Myeloma Patients With Minimal Residual Disease
Our latest quiz highlights the role of testing for minimal residual disease in the management of multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2018 Category: Cancer & Oncology Source Type: news

Molecular Partners says 5 of 8 patients responded in multiple myeloma trial
ZURICH (Reuters) - Molecular Partners said on Friday that five of eight patients with advanced multiple myeloma in a Phase II study showed an objective response to a combination therapy that includes an investigational drug from the Swiss company. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Transplant in Myeloma Ups Survival, but Is Underutilized Transplant in Myeloma Ups Survival, but Is Underutilized
Stem cell transplant improves survival in patients with multiple myeloma, but why is it still underutilized?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: What is the first sign of multiple myeloma?
Spotting the early signs of multiple myeloma means it is easier to treat the disease. However, this type of cancer has no cure and can lead to other conditions developing. Treatment options depend on the individual case. Learn more about the signs of multiple myeloma, and when to see a doctor, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 12, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (car...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

License Not Renewed for UAMS' Myeloma Institute Director
The state medical bBoard will not renew the educational license of Dr. Gareth Morgan, director of the UAMS Myeloma Institute, until he completes a course for distressed physicians. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - June 8, 2018 Category: American Health Source Type: news

Bluebird Myeloma Treatment Delays Cancer Progression Bluebird Myeloma Treatment Delays Cancer Progression
Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small phase I study presented on Friday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Daratumumab/Carfilzomib Combo Effective in Lenalidomide-Refractory MM
Leah LawrenceJun 4, 2018In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Pomalidomide Combo PVd Ups PFS in Lenalidomide-Exposed Myeloma
Leah LawrenceJun 3, 2018OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Once-Weekly Bests Twice-Weekly Carfilzomib in R/R Multiple Myeloma
Leah LawrenceJun 2, 2018A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Genomics Revolution Taking Off in Multiple Myeloma
John SchieszerJun 2, 2018Risk stratification is leading to increasing numbers of new molecular targets in multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Cellular Therapies for Multiple Myeloma: A Paradigm Shift
John SchieszerJun 1, 2018Therapy with CAR T cells may benefit patients with highly refractory multiple myeloma, said U Penn ’s Adam Cohen at ASCO 2018. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Bluebird Bio's " Impressive " Killer T-Cells Battle Myeloma, But Are Not A Cure Yet
New data show that at a high dose, the CAR-T therapy developed by Bluebird and Celgene shrank tumor in 95 percent of patients and made cancer undetectable in 50 percent. The cancer still returned for most patients. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 1, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:CELG NASDAQ:BLUE Source Type: news

Bluebird myeloma treatment delays cancer progression: trial
CHICAGO (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday. (Source: Reuters: Health)
Source: Reuters: Health - June 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS ® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen Prespecified Interim Analysis Presented Today During Oral Session at ASCO 2018 and Simultaneously Published in The Lancet Oncology THOUSAND OAKS, Calif., June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS® (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-...
Source: Amgen News Release - June 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer Multi-Year Agreements Build on Long-Term Partnership in Immuno-Oncology, Including BiTE® Therapies and now CAR T Programs THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung ...
Source: Amgen News Release - May 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

MD Anderson and Amgen to accelerate early-stage treatments for several cancer types
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - May 30, 2018 Category: Pharmaceuticals Source Type: news

Legend Announces FDA Clearance of IND Application on CAR-T Immuno-cell Therapy for the Treatment of Multiple Myeloma
LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen PISCATAWAY, N.J., May 30, 2018 -- (Healthcare Sales & Marketing Network) -- Legend Biotech, a subsidiary of GenScript Biotech Corporation... Biopharmaceuticals, Oncology, FDA Legend Biotech, GenScript Biotech, Janssen, CAR-T therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 30, 2018 Category: Pharmaceuticals Source Type: news

Discovery of Genes Linked to Myeloma Onset May Drive Personalized Tx
A UK team found multiple targets of non-coding mutations, highlighting the importance of broadening the search for cancer drivers into the regulatory genome. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

Morning Break: New Myeloma Tx; New EpiPen Shortage? Ticked Off by CDC
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 9, 2018 Category: Psychiatry Source Type: news